Our India CSR initiatives
Partnering India to eliminate Lymphatic Filariasis (or Elephant Foot):
As a key partner in the fight against Neglected Tropical Diseases (NTDs), GSK has identified elimination of Lymphatic Filariasis (LF) as the lead CSR project in India. We have committed to donate Albendazole for attacking LF in support of the London Declaration and WHO 2020 Roadmap on NTDs.
About Lymphatic Filariasis:
Lymphatic Filariasis (LF), or Elephantiasis (popularly known as elephant foot), is a devastating infection spread by mosquitoes and is estimated to be one of the leading causes of disability worldwide.
- It affects 120 million people in 72 countries around the world. Another 1.3 billion people (one-fifth of the world’s population) are at risk of infection.
- In India, indigenous cases of LF have been reported from about 250 districts in 20 states/Union Territories.
- People with LF are less able to resist common skin infections, resulting in a cruel cycle of fevers and painful swellings.
- LF is not life threatening, but those who are affected often suffer during the peak of their years. They may experience both disfigurement and extreme emotional distress.
- Many people with LF are unable to work, which usually leads to a life of poverty.
- A single dose of medicine once a year for five years helps clear the parasite from the bloodstream – thus preventing mosquitoes from transmitting the disease to those who are not infected. But unfortunately, development of the most severe physical disfigurements is irreversible.
GSK is working with our partners to put an end to LF by 2020 by continuing to donate millions of Albendazole tablets to the World Health Organization (WHO) each year.
The population coverage during MDA has improved from 73% in 2004 to 86% in 2014 (Prov.), which has resulted in the overall reduction of microfilaria rate from 1.2% in 2004 to 0.4% in 2014 (Prov.)*.
Mother and child healthcare: newborn survival
Among the various CSR projects undertaken by GSK India, we have identified to address the healthcare need of newborn survival. In India, every year over 7.5 lakh children die within the first 28 days. This translates to 27% of world’s newborn deaths, the highest in the world. What is even more heart breaking is that four out of five newborn deaths result from treatable conditions*. At GSK, we have partnered with ARTH and CARE to address the entire continuum of care for newborn survival in the high burden districts in Rajasthan and Madhya Pradesh. We have partnered to build capacity of the ASHA workers, train the skilled birth attendants, generate awareness and ensure improved facility based and home based newborn care. Our commitment for project on newborn survival is estimated to save lives of over 6,000 newborns over the span of two years.
Our medicines can play a vital role in humanitarian relief efforts in disaster zones. We work in partnership with non-profit organisations and relief charities during times of emergency to donate our products where they are needed, according to World Health Organization guidelines. Our approach is non-partisan and we ensure neutrality in supporting health needs. The amount of products donated depends on demand. We have in the past supported relief efforts for floods in Jammu and Kashmir as well as for Nepal earthquake.
At GSK, we are driven by our mission to improve the quality of human life by enabling people to do more, feel better, live longer and our corporate social responsibility embodies this commitment.